Bispecific Antibodies.

Cancer Treatment.


BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its unique and proprietary BiXAb® technology to create next generation bi- and multi-specific antibodies for oncology.

Next Generation Bi- and Multi-specific Antibodies for disruptive biological approaches

Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed  to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

Our ‘Plug-and-Play’ BiXAb technology generates bi- and multi-specific antibodies, with minimal engineering, from any pair of monoclonal antibodies as building blocks, in a timely and cost-effective manner.


Contact us

14 avenue d'Eylau, 75116 Paris

E-mail us